Systematic Review and Meta-Analysis: Macrolides- and Amoxicillin/Clavulanate-induced Acute Liver Injury

Pili Ferrer1, Justyna Amelio2, Elena Ballarín1,3,4

  • 1Foundation Catalan Institute of Pharmacology, Barcelona, Spain.

Insights

Macrolide antibiotics significantly increase the risk of drug-induced liver injury (DILI). Amoxicillin/clavulanate (AMC) also showed a higher DILI risk, though not statistically significant in this meta-analysis.

Area of Science:

  • Pharmacovigilance
  • Hepatology
  • Drug Safety

Background:

  • Idiosyncratic drug-induced liver injury (DILI) is a known risk associated with antibacterial agents.
  • Macrolides and amoxicillin/clavulanate (AMC) are commonly prescribed antibacterials requiring risk assessment for DILI.

Purpose of the Study:

  • To systematically review and meta-analyze the risk of DILI associated with macrolides and amoxicillin/clavulanate (AMC).

Main Methods:

  • A systematic review and random-effects meta-analysis of studies published between 1980-2014.
  • Searched databases including PubMed, Cochrane Library Plus, Web of Knowledge, clinicaltrials.gov, Livertox, and Toxline.
  • Included studies of all designs (except case reports/series) with placebo or non-user comparators.

Main Results:

  • Macrolides were associated with a summary relative risk of DILI of 2.85 (95% CI 1.81-4.47, p < 0.0001).
  • Amoxicillin/clavulanate (AMC) showed a summary relative risk of DILI of 9.38 (95% CI 0.65-135.41, p = 0.3), with high heterogeneity (I² = 95%).

Conclusions:

  • This meta-analysis quantifies the association between macrolides and AMC with acute liver injury.
  • Despite identified risks, the low incidence of DILI and the therapeutic importance of these antibiotics suggest their benefits may outweigh risks.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
344
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
334
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
472
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
167
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
296